Alkemist Bio
Founded 2023 · 6 employees on LinkedIn · 4 known investors
Find your way into Alkemist Bio
ALKemist Bio develops immunotherapies targeting the ALK oncogene in cancer by engineering autologous T cells with synthetic receptors to recognize and eliminate ALK-positive tumor cells. The company's approach aims to address ALK-driven cancers including lymphoma, neuroblastoma, and non-small cell lung cancer.
Founders & leadership
Alkemist Bio was founded in 2023 by Roberto Chiarle.
RC
Roberto Chiarle
Investors · 4
In the news
Frequently asked questions
- What does Alkemist Bio do?
- ALKemist Bio develops immunotherapies targeting the ALK oncogene in cancer by engineering autologous T cells with synthetic receptors to recognize and eliminate ALK-positive tumor cells. The company's approach aims to address ALK-driven cancers including lymphoma, neuroblastoma, and non-small cell lung cancer.
- Who founded Alkemist Bio?
- Alkemist Bio was founded by Roberto Chiarle in 2023.
- Who are Alkemist Bio's investors?
- Alkemist Bio's investors include Claris Ventures, Club degli Investitori, Italian Angels for Growth, LIFTT.